en

Cabrera-Gomez, Jose A.; Santana, Ernesto; Miro-Gonzalez, Alexis; Gomez, Ariel; Echazabal, Nancy; Quevedo-Sotolongo, Luis; Serrano, Giordano; Casanova, Maria; Gomez, Lazaro; Gonzalez-Quevedo, Alina; Alfaro, Ileana; Vals, Orlando; Cabrera-Nunez, Jose A.; Rodriguez, Aleida & Lopez-Saura, Pedro Abstract Three men and six women (22 to 48 years old) with clinically defined multiple sclerosis (MS), (more than 2 years ill with at least one relapse), were studied. They also had characteristic lesions in the magnetic resonance imaging, oligoclonal immunoglobulin bands in cerebrospinal fluid and no alterations in the sensitive and motor conduction velocity studies of the limbs. Intramuscular recombinant interferon alpha-2b (Heberon alpha R) was administered at 6 million IU weekly during 3 to 48 (average 24) months. Six patients had the relapsing-remitting (RR) course of the disease; 2, the relapsing-progressive (RR-P) and one, the relapsing- remitting-stable (RR-ST) form. The whole group of patients had considerably fewer relapses after treatment than in the 2 previous years. The decrease was from 11 to 3 relapses, less intense and with shorter duration, taking patients with RR-MS only. Three of these patients did not relapse at all during 24, 30 and 42 months of treatment. Three RR-MS patients improved their disability scores (Kurtzke scale) in one point or more, and 2 in less than one point. There was improvement in the neurologic evaluation scores (Scripps) in all patients but one with the RR-ST form of disease. The treatment was generally well tolerated. Keywords recombinant interferon alpha-2b, multiple sclerosis, clinical trial

es

Tratamiento de la esclerosis multiple con interferon alfa-2b recombinante. Estudio piloto Cabrera-Gomez, Jose A.; Santana, Ernesto; Miro-Gonzalez, Alexis; Gomez, Ariel; Echazabal, Nancy; Quevedo-Sotolongo, Luis; Serrano, Giordano; Casanova, Maria; Gomez, Lazaro; Gonzalez-Quevedo, Alina; Alfaro, Ileana; Vals, Orlando; Cabrera-Nunez, Jose A.; Rodriguez, Aleida & Lopez-Saura, Pedro Resumen Se estudiaron 6 mujeres y 3 hombres (edad de 22 a 48 anos) con esclerosis multiple (EM) clinica definida (mas de 2 anos de evolucion con al menos una recaida), lesiones caracteristicas en imagenes de resonancia magnetica, bandas oligoclonales de inmunoglobulinas en liquido cefalorraquideo y sin alteraciones en las velocidades de conduccion sensitiva y motora de las extremidades. Se administro 6 millones de UI de interferon alfa-2b recombinante (Heberon alfa R) intramuscular semanal durante 3 a 48 (promedio 24) meses. Seis pacientes tenian la forma evolutiva exacerbacion- remision (ER), 2 la exacerbacion-progresiva (ER-SP) y una la exacerbacion- remision-estable (ER-ES). Despues del tratamiento hubo menos recaidas de todo el grupo en comparacion con las observadas en los 2 anos anteriores. En el grupo ER, de 11 recaidas solo se produjeron 3, de menor intensidad y duracion. Tres de estos pacientes no tuvieron recaidas durante 24, 30 y 42 meses de tratamiento. Hubo mejoria de un punto o mas en las evaluaciones de la escala de inhabilidad de Kurtzke en 3 pacientes con forma EM-ER y menor de un punto en otros 2. En todos los pacientes excepto una con la forma ER- ES hubo mejoria en la escala de evaluacion neurologica Scripps. El tratamiento fue bien tolerado. Palabras-clave interferon alfa-2b recombinante, esclerosis multiple, estudio clinico

© Copyright 1997 Elfos Scientiae
Alternative site location: http://elfosscientiae.cigb.edu.cu/Archivo.asp?Id=6